BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Antimicrobial Activity of Mupirocin, Daptomycin, Linezolid, Quinupristin/Dalfopristin and Tigecycline against Vancomycin-Resistant Enterococci (VRE) from Clinical Isolates in Korea (1998 and 2005)

  • Published : 2007.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

It is a hot clinical issue whether newly approved antimicrobial agents such as daptomycin, linezolid, quinupristin/dalfopristin (synercid) and tigecycline are active enough to be used for infections caused by vancomycin resistant bacteria. We performed susceptibility tests for mupirocin, which is in widespread clinical use in Korea, and four new antimicrobials, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline, against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium isolated from Korean patients in 1998 and 2005 to evaluate and compare the in vitro activity of these antimicrobials. Among these agents, quinupristin/dalfopristin, which is rarely used in hospitals in Korea, showed relatively high resistance to several vancomycin-resistant enterococci (VRE) isolated in 2005. Likewise, daptomycin, linezolid and tigecycline have not yet been in clinical use in Korea. However, our results showed that most of the 2005 VRE isolates were already resistant to linezolid and daptomycin (highest minimum inhibitory concentration (MIC) value >$100{\mu}g$/ml). Compared with the other four antimicrobial agents tested in this study, tigecycline generally showed the greatest activity against VRE. However, four strains of 2005 isolates exhibited resistance against tigecycline (MIC >$12.5{\mu}g$/ml). Almost all VRE were resistant to mupirocin, whereas all E. faecium isolated in 1998 were inhibited at concentrations between $0.8\sim1.6{\mu}g$/ml. In conclusion, resistances to these new antimicrobial agents were exhibited in most of VRE strains even though these new antibiotics have been rarely used in Korean hospitals.

Keywords

References

  1. Acarturk, E., Attila, G., Bozkurt, A., Akplnar, O., Matyar, S. and Seydaoglu, G. (2005) Insertion/deletion polymorphism of the angiotensin converting enzyme in coronary artery disease in Southern Turkey. J. Biochem. Mol. Biol. 38, 486-490. https://doi.org/10.5483/BMBRep.2005.38.4.486
  2. Akins, R. L. and Rybak, M. J. (2001) Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycinresistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus isolates in and in vitro pharmacodynamic model with simulated endocardial vegetation. Antimicrob. Agents Chemother. 45, 454-459. https://doi.org/10.1128/AAC.45.2.454-459.2001
  3. Betriu, C., Gomez, M., Rodriguez-Avial, I., Culebras, E. and Picazo, J. J. (2005) In vitro activity of tigecycline against ampicillinresistant Haemophilus influenzae isolates. J. Antimicrob. Chemother. 55, 809-810. https://doi.org/10.1093/jac/dki096
  4. Bouchillon, S. K., Hoban, D. J., Johnson, B. M., Stevens, T. M., Dowzicky, M. J., Wu, D. H. and Bradford, P. A. (2005) In vitro evaluation of tigecycline and comparative agents in 3,049 clinical isolates: 2001 to 2002. Diagn. Microbiol. Infect. Dis. 51, 291-295. https://doi.org/10.1016/j.diagmicrobio.2004.11.006
  5. Centers for Disease Control and Prevention (1993) Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. Morbid. Mortal. Weekly Rep. 42, 597-599.
  6. Choi, S. S., Kim, B. S. and Ha, N. J. (2002) Isolation, identification and characterization of vancomycin-resistant enterococci from raw milk. J. Microbiol. 40, 170-172.
  7. Choi, J. H., Zhang, P. C., Park, K. W., Cho, Y. S. and Oh, B. H. (2005) The association between the T102C polymorphism of the HTR2A serotonin receptor gene and HDL cholesterol level in Koreans. J. Biochem. Mol. Biol. 38, 238-242. https://doi.org/10.5483/BMBRep.2005.38.2.238
  8. Diekema, D. J. and Jones, R. N. (2001) Oxazolidinone antibiotics. Lancet 358, 1975-1982. https://doi.org/10.1016/S0140-6736(01)06964-1
  9. Emori, T. G. and Gaynes, R. P. (1993) An overview of nosocomial infections, including the role of microbiology laboratory. Clin. Microb. Drug Resist. 6, 313-318.
  10. Fritsche, T. R., Sader, H. S., Stilwell, M. G., Dowzicky, M. J and Jones, R. N. (2005a) Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 52, 187-193. https://doi.org/10.1016/j.diagmicrobio.2005.05.004
  11. Fritsche, T. R., Sader, H. S., Stilwell, M. G., Dowzicky, M. J. and Jones, R. N. (2005b) Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis. 52, 195-201. https://doi.org/10.1016/j.diagmicrobio.2005.05.003
  12. Fuchs, P. C., Barry, A. L. and Brown, S. D. (2000) Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. 38, 51-58. https://doi.org/10.1016/S0732-8893(00)00164-4
  13. Hsueh, P. R., Chen, W. H., Teng, L. J and Luh, K. T. (2005) Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int. J. Antimicrob. Agents 26, 43-49. https://doi.org/10.1016/j.ijantimicag.2005.04.007
  14. Jones, R. N. (2003) Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a fiveyear summary from the Sentry Antimicrobial Surveillance Program (1997-2001). Semin. Respir. Crit. Care Med. 24, 121-133. https://doi.org/10.1055/s-2003-37923
  15. Kim, J. M. and Song, Y. G. (1998) Vancomycin-resistant enterococcal infections in Korea. Yonsei Med. J. 39, 562-568. https://doi.org/10.3349/ymj.1998.39.6.562
  16. Kim, S. M., Shim, E. S. and Seong, C. N. (2001) Prevalence and antibiotic susceptibility of vancomycin-resistant enterococci in chicken intestines and fecal samples from healthy young children and intensive care unit patients. J. Microbiol. 39, 116-120.
  17. Klare, I., Heier, H., Claus, H., Reissbrodt, R. and Witte, W. (1995) VanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. Fems Microbiol. Lett. 125, 165-172. https://doi.org/10.1111/j.1574-6968.1995.tb07353.x
  18. LaPlante, K. L. and Rybak, M. J. (2004) Clinical glycopeptideintermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn. Microbiol. Infect. Dis. 50, 125-130. https://doi.org/10.1016/j.diagmicrobio.2004.06.014
  19. Meka, V. G. and Gold, H. S. (2004) Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39, 1010-1015. https://doi.org/10.1086/423841
  20. Moellering, R. C. (1992) Emergence of Enterococcus as a significant pathogen. Clin. Infect. Dis. 14, 1173-1178. https://doi.org/10.1093/clinids/14.6.1173
  21. Nathwani, D. (2005) Tigecycline: clinical evidence and formulary positioning. Int. J. Antimicrob. Agents 25, 185-192. https://doi.org/10.1016/j.ijantimicag.2004.11.006
  22. National Committee for Clinical Laboratory Standards (NCCLS) (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. Wayne PA: NCCLS.
  23. National Committee for Clinical Laboratory Standards (NCCLS) (2005) Performance standards for antimicrobial susceptibility testing, 15th information supplement M100-S15. Wayne PA: NCCLS.
  24. Package insert (2003) Cubicin (daptomycin for infection). Lexington MA. (Cubist Phamaceuticals, Inc.) Available at http://www.cubist.com/shared/cubicin_label.pdf. Accessed on September 22, 2003.
  25. Patel, R. (2003) Clinical impact of vancomycin-resistant enterococci. J. Antimicrob. Chemother. 51 (Suppl.), 13-21.
  26. Raad, I., Hachem, R. and Hanna, H. (2001) Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob. Agents Chemother. 45, 3202-3204. https://doi.org/10.1128/AAC.45.11.3202-3204.2001
  27. Raad, I., Hachem, R., Hanna, H., Afif, C., Escalante, C., Kantarjian, H. and Rolston, K. (2004) Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections J. Antimicrob. Chemother. 53, 646-649. https://doi.org/10.1093/jac/dkh144
  28. Ross, J. E., Anderegg, T. R., Sader, H. S., Fritsche, T. R. and Jones, R. N. (2004) Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn. Microbiol. Infect. Dis. 52, 53-58.
  29. Sader, S. H., Fritsche, T. R. and Jones, R. N. (2005) Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Diagn. Microbiol. Infect. Dis. 53, 329-332. https://doi.org/10.1016/j.diagmicrobio.2005.07.001
  30. Sader, H. S., Jones, R. N., Dowzicky, M. J. and Fritsche, T. R. (2005) Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. 52, 203-208. https://doi.org/10.1016/j.diagmicrobio.2005.05.002
  31. Sader, H. S., Streit, J. M., Fritsche, T. R. and Jones, R. N. (2004) Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. Diagn. Microbiol. Infect. Dis. 50, 201-204. https://doi.org/10.1016/j.diagmicrobio.2004.07.002
  32. Sakouloas, G., Eliopoulos, G. M., Alder, J. and Thauvin-Eliopoulos, C. (2003) Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 1714-1718. https://doi.org/10.1128/AAC.47.5.1714-1718.2003
  33. Smith, P. F., Booker, B. M., Ogundele, A. B. and Kelchin, P. (2005) Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. Diagn. Microbiol. Infect. Dis. 52, 255-259. https://doi.org/10.1016/j.diagmicrobio.2005.02.015
  34. Steenbergen, J. N., Alder, J., Thorne, G. M. and Talley, F. P. (2005) Dpatomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55, 283-288. https://doi.org/10.1093/jac/dkh546
  35. Streit, J. M., Jones, R. N. and Sader, H. S. (2004) Daptomycin activity and spectrum: A worldwide sample of 6,737 Grampositive organisms. J. Antimicrob. Chemother. 53, 669-674. https://doi.org/10.1093/jac/dkh143
  36. Wenzel, R. P. (2004) The antibiotic pipeline-challenges, costs and values. N. Engl. J. Med. 351, 523-526. https://doi.org/10.1056/NEJMp048093
  37. Wesson, K. M., Lerner, D. S., Silverberg, N. B. and Weinberg, J. M. (2004) Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Dis. Mon. 50, 395-406. https://doi.org/10.1016/j.disamonth.2004.05.010
  38. Witte, W. (1997) Impact of antibiotic use in animal feeding on resistance of bacterial pathogens in humans. Ciba. Found. Symp. 207, 61-71.
  39. World Health Organization (WHO) WHO Global strategy for containment of antimicrobial resistance. WHO/CDS/CSR/DRS/2001.2.
  40. Yang, J. W., Lee, D. K., Kim, Y. A., Kang, B. Y., Kim, K. J. and Ha, N. J. (2007) Occurrence of the van genes in Enterococcus faecalis and Enterococcus faecium from clinical isolates in Korea. Arch. Pharm. Res. 30, 329-336. https://doi.org/10.1007/BF02977614

Cited by

  1. Characterization ofEnterocccus faecalisIsolates from the Pork Meat Production Chain and Comparison with Human Clinical Isolates vol.33, pp.2, 2013, https://doi.org/10.1111/jfs.12039
  2. Prevalence of phenotypic resistance of Staphylococcus aureus isolates to macrolide, lincosamide, streptogramin B, ketolid and linezolid antibiotics in Turkey vol.14, pp.1, 2010, https://doi.org/10.1016/S1413-8670(10)70003-9
  3. An update on emerging therapies for urinary tract infections vol.22, pp.1, 2017, https://doi.org/10.1080/14728214.2017.1293650
  4. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies vol.68, pp.suppl 2, 2013, https://doi.org/10.1093/jac/dkt140
  5. Total Occlusive Ionic Silver-Containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection vol.221, pp.2, 2015, https://doi.org/10.1016/j.jamcollsurg.2015.04.019
  6. Antibiotic resistance and assessment of food-borne pathogenic bacteria in frozen foods vol.32, pp.12, 2009, https://doi.org/10.1007/s12272-009-2213-y
  7. Resistance to and synthesis of the antibiotic mupirocin vol.8, pp.4, 2010, https://doi.org/10.1038/nrmicro2278
  8. Flow Cytometry Approach Study of Enterococcus faecalis Vancomycin Resistance by Detection of Vancomycin@FL Binding to the Bacterial Cells vol.61, pp.5, 2010, https://doi.org/10.1007/s00284-010-9628-z
  9. Biological activities of pargamicin A, a novel cyclic peptide antibiotic from Amycolatopsis sp. vol.63, pp.6, 2010, https://doi.org/10.1038/ja.2010.29
  10. Peritoneal dialysis-associated peritonitis caused by vancomycin-resistant Enterococcus: Comprehensive review on treatment options vol.17, pp.2, 2015, https://doi.org/10.1016/j.hkjn.2015.03.003
  11. A novel nano drug delivery system based on tigecycline-loaded calciumphosphate coated with poly-dl-lactide-co-glycolide vol.21, pp.1, 2010, https://doi.org/10.1007/s10856-009-3854-6
  12. Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis vol.67, pp.9, 2012, https://doi.org/10.1093/jac/dks181
  13. Susceptibility of Glycopeptide-Resistant Enterococci to Linezolid, Quinupristin/dalfopristin, Tigecycline and Daptomycin in a Tertiary Greek Hospital vol.46, pp.4, 2014, https://doi.org/10.3947/ic.2014.46.4.253
  14. Daptomycin Nonsusceptible Enterococci: An Emerging Challenge for Clinicians vol.52, pp.2, 2011, https://doi.org/10.1093/cid/ciq113